Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 421-423

  Jones, Mark E ^a,d   Visser, Maarten R ^a   Klootwijk, Miriam ^a   Heisig, Peter ^b   Verhoef, Jan ^a   Schmitz, Franz Josef ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MRL Pharmaceutical Services   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CROSS RESISTANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0032994955     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.421     Document Type: Article

References (17)

1. Aumercier, M., S. Bouhallab, M. L. Capmau, and F. Le Goffic. 1992. RP 59500: a proposed mechanism for its bacteriocidal activity. J. Antimicrob. Chemother. 30(Suppl. A):9-14.
2. Brumfitt, W., J. Hamilton-Miller, and S. Shah. 1992. In vitro activity of RP 59500, a new semi-synthetic streptogramin antibiotic against Grant positive bacteria. J. Antimicrob. Chemother. 30(Suppl. A):122-177.
3. Dalhoff, A., U. Peterson, and R. Enderman. 1996. In vitro activities of BAY12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
4. Daly, J. S., G. M. Eliopoulos, E. Reiszner, and R. C. Moellering. 1988. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J. Antimicrob. Chemother. 21:721-730.
5. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 1998. Comparative activities of clinafloxacin against gram-positive and -negative bacteria. Antimicrob. Agents Chemother. 42:1269-1273.
6. Felmingham, D., M. J. Robbins, K. Ingley, I. Mathias, H. Bhogal, A. Leaky, G. L. Ridgeway, and R. N. Gruneburg. 1997. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 39(Suppl. B):43-49.
7. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rusenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
8. Fuchs, P. C., A. L. Barry, and S. D. Brown. 1998. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers. Antimicrob. Agents Chemother. 42:1274-1277.
9. Goldstein, F. W., and J. F. Acar. 1995. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49(Suppl. 2):36-42.
10. Lin, A. H., R. W. Murray. T. J. Vidmar, and K. R. Marotti. 1997. The oxazolidinone eperezolid hinds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. 41:2127-2131.
11. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing. M100-S8. National Committee for Clinical Laboratory Standards. Wayne, Pa.
12. Schmitz, F. J., B. Hofmann, B. Hansen, S. Scheuring, M. Lückefahr, M. Klootwijk, J. Verhoef, A. Fluit, H.-P. Heinz, K. Köhrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, and moxifloxacin MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:81-84.
13. Schmitz, F. J., B. Hofmann, J. Verhoef, M. Finken-Eigen, H. Idel, U. Hadding, H.-P. Heinz, and K. Köhrer. 1997. Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR. J. Med. Microbiol. 46:773-778.
14. Schmitz, F. J., M. Steiert, H.-V. Tichy, J. Verhoef, H.-P. Heinz, K. Köhrer, and M. E. Jones. 1998. Typing of methicillin-resistant Staphylococcus aureus isolates from Düsseldorf by six genotypic methods. J. Med. Microbiol. 47: 341-351.
15. Smith, K. R., and C. G. Cobbs. 1992. In vitro activity of AT-4140 (sparfloxacin) and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur. J. Clin. Microbiol. Infect. Dis. 11:55-58.
16. Visser, M. R., M. Rozenberg-Arska, H. Beumer, I. M. Hoepelman, and J. Verhoef. 1991. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob. Agents Chemother. 35: 858-868.
17. Wiedemann, B., and P. Heisig. 1997. Antibacterial activity of grepafloxacin. J. Antimicrob. Chemother. 40(Suppl. A):19-25.